| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
IRLAB Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 16.15 |
| 52 Week High | SEK 20.20 |
| 52 Week Low | SEK 5.58 |
| Beta | 0.71 |
| 11 Month Change | 17.03% |
| 3 Month Change | 40.43% |
| 1 Year Change | 100.37% |
| 33 Year Change | -72.44% |
| 5 Year Change | -61.32% |
| Change since IPO | 36.86% |
Recent News & Updates
Recent updates
IRLAB Therapeutics (STO:IRLAB A) Has Debt But No Earnings; Should You Worry?
Jun 06
Here's Why We're Watching IRLAB Therapeutics' (STO:IRLAB A) Cash Burn Situation
Jan 04Here's Why IRLAB Therapeutics (STO:IRLAB A) Must Use Its Cash Wisely
Sep 21We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully
Mar 18IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans
Dec 01We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit
May 19We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow
Sep 11We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow
Apr 30What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?
Mar 19We Think IRLAB Therapeutics (STO:IRLAB A) Can Afford To Drive Business Growth
Jan 25Our View On IRLAB Therapeutics' (STO:IRLAB A) CEO Pay
Dec 21What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?
Nov 25
Shareholder Returns
| IRLAB A | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -1.8% | -3.2% | -7.2% |
| 1Y | 100.4% | 70.7% | 10.7% |
Return vs Industry: IRLAB A exceeded the Swedish Pharmaceuticals industry which returned 70.7% over the past year.
Return vs Market: IRLAB A exceeded the Swedish Market which returned 9.9% over the past year.
Price Volatility
| IRLAB A volatility | |
|---|---|
| IRLAB A Average Weekly Movement | 10.9% |
| Pharmaceuticals Industry Average Movement | 10.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: IRLAB A's share price has been volatile over the past 3 months.
Volatility Over Time: IRLAB A's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 32 | Kristina Torfgard | www.irlab.se |
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson’s disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 research programs for the treatment of neurodegenerative disorders and ageing; IRL1117, a drug candidate developed for once-daily oral treatment for the hallmark symptoms of Parkinson’s; and IRL757 to treat apathy in neurological diseases.
IRLAB Therapeutics AB (publ) Fundamentals Summary
| IRLAB A fundamental statistics | |
|---|---|
| Market cap | SEK 837.67m |
| Earnings (TTM) | -SEK 119.45m |
| Revenue (TTM) | SEK 41.59m |
20.1x
P/S Ratio-7.0x
P/E RatioIs IRLAB A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IRLAB A income statement (TTM) | |
|---|---|
| Revenue | SEK 41.59m |
| Cost of Revenue | SEK 115.50m |
| Gross Profit | -SEK 73.91m |
| Other Expenses | SEK 45.54m |
| Earnings | -SEK 119.45m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 30, 2024
| Earnings per share (EPS) | -2.30 |
| Gross Margin | -177.74% |
| Net Profit Margin | -287.25% |
| Debt/Equity Ratio | 77.6% |
How did IRLAB A perform over the long term?
See historical performance and comparison